Company / Financials
Vanda Pharmaceuticals Inc. Financials
FY2011-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$192.6M
FY2025 · -24.3% YoY
Net Income
$2.5M
FY2025 · -60.0% YoY
Profit Margin
1.3%
FY2025 · net income / revenue
ROE
0.5%
FY2025 · return on equity
Total Assets
$488.9M
FY2025
Total Debt
-
FY2025
Equity
$538.5M
FY2025
ROA
0.5%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score -3.96 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$192.6M-24.3% YoYNet Income HistoryProfit after all expenses and taxes$2.5M-60.0% YoYGross Profit HistoryRevenue minus cost of goods sold-Cost of Revenue HistoryDirect costs of producing goods and services sold-Operating Income HistoryProfit from core business operations before interest and taxes-$14.0M-320.4% YoYSG&A Expense HistorySelling, general, and administrative expenses$112.9M-17.3% YoYR&D Expense HistoryResearch and development spending$76.8M-10.4% YoYIncome Tax HistoryTotal income tax expense$3.8M-23.8% YoYEPS (Basic) HistoryBasic earnings per share$0.04-63.6% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles$0.04-63.6% YoY